EUVIMEDEUVIMED entdecken
Crossref

Evaluating Antibacterial Efficacy of Cefiderocol and Cefepime/Taniborbactam Against OXA-48-Like and NDM-Expressing Enterobacterales: An In-Vitro and In-Silico Approach

Mohanraj Gopikrishnan, Sriroopreddy Ramireddy, Yamuna Devi Bakathavatchalam, Rinku Polachirakkal Varghese, D Thirumal Kumar, Binesh Lal, Abi Manesh, Kamini Walia, Balaji Veeraraghavan, C George Priya Doss

Current Microbiology · 2025

DOI: 10.1007/s00284-025-04543-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Microbiology, 2025. Verfasst von Mohanraj Gopikrishnan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrative Genomics, Department of Integrative Biology, School of Biosciences and Technology, Vellore Institute of Technology (VIT), V…. Hauptthemen laut MEDLINE: Cefepime, Cephalosporins, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Indian Council of Medical Research (ICMR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New Delhi metallo-β-lactamase (NDM)-producing enterobacterales infections pose significant challenges due to limited treatment options. Recently, a triple combination of ceftazidime/avibactam and aztreonam has been utilized to combat these infections. However, a four-amino-acid insertion in PBP3 and/or the ampC β-lactamase has been linked to the development of resistance to this triple combination in several recent investigations. To evaluate the effectiveness of cefiderocol and cefepime/tazobactam using both in-vitro and in-silico methods, this study examines current non-duplicate isolates of carbapenem-resistant E. coli (n = 40) and carbapenem-resistant K. pneumoniae (n = 40) derived from blood cultures. The MIC of cefepime/taniborbactam and cefiderocol was ascertained using the micro-broth dilution technique. Additionally, computational analysis was performed using molecular docking with AutoDock tools and dynamic simulation with GROMACS, followed by MM-PBSA analysis for a duration of 50 ns. In MIC assays, cefiderocol and cefepime/taniborbactam showed minimal effectiveness against NDM-producing K. pneumoniae and E. coli that possessed OXA-48-like traits. However, both antibiotics showed strong affinity against OXA-48-like producers. Docking studies varied from -4.3 to -8.1 kcal/mol, indicating a higher binding affinity and stronger hydrogen bond formation in OXA-48-like compared to NDM producers. All complexes exhibited stable conformational states, as indicated by analyses of the RMSD, RMSF, Rg, SASA, and hydrogen bond trajectories. Further evidence supports stable BL/BLI interactions within binding sites, mediated by PCA, FEL, and DCCM, as indicated by the binding free energy. Computational studies confirmed better binding affinity for both OXA-48-like and NDM. However, in-vitro studies demonstrated that cefepime/taniborbactam and cefiderocol represent viable alternative options, specifically for OXA-48-like producers, as their effectiveness is significantly compromised in the presence of NDM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefepimeCephalosporinsbeta-LactamasesAnti-Bacterial AgentsEscherichia coliKlebsiella pneumoniaeBorinic AcidsMicrobial Sensitivity TestsHumansMolecular Docking SimulationCefiderocolBacterial ProteinsEnterobacteriaceae InfectionsComputer SimulationCarboxylic Acids

Substanzen

CefepimeCephalosporinsbeta-LactamasesAnti-Bacterial AgentsCefiderocoltaniborbactamBorinic AcidsBacterial ProteinsCarboxylic Acids

Autor:innen und Institutionen

  • Laboratory of Integrative Genomics, Department of Integrative Biology, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.
  • Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, 632014, India.
  • Meenakshi Academy of Higher Education and Research, Chennai, Tamil Nadu, 600078, India.
  • Department of Infectious Disease, Christian Medical College, Vellore, Tamil Nadu, 632014, India.
  • Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
  • Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, 632014, India. vbalaji@cmcvellore.ac.in.

Förderung

  • Indian Council of Medical Research (ICMR)

Zitieren

APA

Gopikrishnan, M., Ramireddy, S., Bakathavatchalam, Y. D., Varghese, R. P., Kumar, D. T., Lal, B., Manesh, A., Walia, K., Veeraraghavan, B., & Priya Doss, C. G. (2025). Evaluating Antibacterial Efficacy of Cefiderocol and Cefepime/Taniborbactam Against OXA-48-Like and NDM-Expressing Enterobacterales: An In-Vitro and In-Silico Approach. Current Microbiology. https://doi.org/10.1007/s00284-025-04543-0

Vancouver

Gopikrishnan M, Ramireddy S, Bakathavatchalam YD, Varghese RP, Kumar DT, Lal B, et al. Evaluating Antibacterial Efficacy of Cefiderocol and Cefepime/Taniborbactam Against OXA-48-Like and NDM-Expressing Enterobacterales: An In-Vitro and In-Silico Approach. Current Microbiology. 2025. doi:10.1007/s00284-025-04543-0

BibTeX
@article{Gopikrishnan2025,
  author = {Gopikrishnan, Mohanraj and Ramireddy, Sriroopreddy and Bakathavatchalam, Yamuna Devi and Varghese, Rinku Polachirakkal and Kumar, D Thirumal and Lal, Binesh and Manesh, Abi and Walia, Kamini and Veeraraghavan, Balaji and Priya Doss, C George},
  title = {Evaluating Antibacterial Efficacy of Cefiderocol and Cefepime/Taniborbactam Against OXA-48-Like and NDM-Expressing Enterobacterales: An In-Vitro and In-Silico Approach},
  journal = {Current Microbiology},
  year = {2025},
  doi = {10.1007/s00284-025-04543-0}
}
Kostenlos starten →